Relmada Therapeutics (RLMD) Other Non-Current Liabilities (2014 - 2018)

Relmada Therapeutics (RLMD) has reported Other Non-Current Liabilities for 5 consecutive years, with $4.2 million the latest figure, recorded in Q2 2018.

• In Q2 2018, Other Non-Current Liabilities rose 2285.31% year-over-year to $4.2 million; the TTM figure through Jun 2018 stood at $4.2 million (up 2285.31% YoY), while the FY2018 annual figure was $4.2 million, up 2285.31% from the prior year.
• Other Non-Current Liabilities rose to $4.2 million in Q2 2018 per RLMD's latest filing, from $175853.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $25.6 million in Q2 2014 and bottomed at $100000.0 in Q4 2014.
• Historically, Other Non-Current Liabilities has averaged $4.1 million across 5 years, with a median of $139421.0 in 2017.
• Annual changes were most pronounced in 2016 — Other Non-Current Liabilities sank 93.63% — and 2018, when it soared 2285.31%.
• Relmada Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2014, then surged by 13901.37% to $14.0 million in 2015, then plunged by 99.02% to $137078.0 in 2016, then increased by 28.29% to $175853.0 in 2017, then jumped by 2285.31% to $4.2 million in 2018.
• Business Quant data shows RLMD's Other Non-Current Liabilities at $4.2 million in Q2 2018, $175853.0 in Q2 2017, and $139421.0 in Q1 2017.